

Review Form 3

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_128435
Title of the Manuscript:	Nelarabine in T-Cell Acute Lymphoblastic Leukemia: An Analysis of the Literature
Type of the Article	Review Article

General guidelines for the Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guidelines for the Peer Review process, reviewers are requested to visit this link:

<https://r1.reviewerhub.org/general-editorial-policy/>

Important Policies Regarding Peer Review

Peer review Comments Approval Policy: <https://r1.reviewerhub.org/peer-review-comments-approval-policy/>

Benefits for Reviewers: <https://r1.reviewerhub.org/benefits-for-reviewers>

Review Form 3

PART 1: Comments

	Reviewer's comment	Author's Feedback <i>(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.	<ul style="list-style-type: none"> - It is an interesting topic and an area of valuable research. - Nelarabine is the only drug approved for patients with relapsed or refractory T-ALL - Nelarabine combination therapy is well tolerated and associated with a higher complete remission and improved Overall survival than Nelarabine monotherapy, despite causing higher rates of anemia and thrombocytopenia. - Researchers investigated and still studying the use of nelarabine in different ways, both by itself and with other cancer drugs, and focused on preventing relapse condition. 	
Is the title of the article suitable? (If not please suggest an alternative title)	<ul style="list-style-type: none"> - I think not suitable and better to be changed and must be more informative. - As a suggestion (Impact of Nelarabine in T-Cell Acute Lymphoblastic Leukaemia) 	
Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here.	<p>I think it needs upgrades and rewrite because:</p> <ul style="list-style-type: none"> - An abstract for a review paper is typically 150–250 words. It should be concise but comprehensive, offering a clear view of the review's scope and significance. - The purpose of a review paper abstract is to provide a concise and clear overview of the reviewed literature and to give readers a sense of what the review covers. 	
Is the manuscript scientifically, correct? Please write here.	<p>Yes. Needs to rephrase sentences, use correct pronoun usage, choose a synonym,</p>	
Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.	<p>References are sufficient and updated. Please doi should be added.</p>	
Is the language/English quality of the article suitable for scholarly communications?	<p>The text is satisfactory but requires a thorough check of grammar.</p>	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<p><i>(If yes, Kindly please write down the ethical issues here in details)</i></p>	

Reviewer Details:

Name:	May Mohammed Ali Hussen
Department, University & Country	Sudan University of Science and Technology, Sudan